Friday, January 27, 2023
Market-Reporter
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
Market-Reporter
No Result
View All Result
Home Europe & Middle East

Spherix Global Insights Expands Expert Coverage of IgA Nephropathy Into EU Markets and Announces Upcoming Second Annual US Patient Audit

MtR by MtR
October 28, 2021
in Europe & Middle East
0


EXTON, Pa., Oct. 28, 2021 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology-based research and insights, announced this month the release of Market Dynamix™: IgA Nephropathy (EU), their first annual EU5 research on IgA nephropathy (IgAN). This was published in conjunction with a parallel US-based IgAN report, and publications focusing on focal segmental glomerulosclerosis (FSGS), Alport syndrome, and membranous nephropathy.

Spherix’s research incorporated feedback from 246 nephrologists across the UK, Germany, France, Italy, and Spain. Overall, survey respondents across the EU5 rate glomerular diseases as highly challenging to manage and consider them as having a very high unmet need for new treatment options, with IgAN falling towards the middle.

Related articles

Heptanoic Acid Market Size to Grow by USD 604.03 million with 41% contribution from Europe, 17,000+ Technavio Reports

August 10, 2022

Caffeine Substitute Market to Observe Highest Growth of USD

August 10, 2022

The lack of effective treatment options for IgAN is one of nephrologists’ greatest challenges with the disease, followed by the difficulty in determining which patients to treat aggressively. In fact, EU5 nephrologists consider less than two-thirds of their IgAN patients as “optimally managed” – with some of the lowest rates in Spain and the UK.

Across the EU5, nephrologists identify approximately one-quarter of their IgAN patients as having nephrotic syndrome, with those physicians in the UK on the lower edge and those in Italy notably higher. One-in-five patients overall are classified as having “severe” disease, and one-in-seven are considered to be progressing rapidly, again with regional differences highlighting various opinions and patient types.  All of this data is comparable to that found in Spherix’s Market Dynamix™: IgA Nephropathy (US) service, leveraging survey data from 100 US practicing physicians.

Kidney biopsy rates and approaches to treating patients with steroids – often the only option for progressing disease – also vary considerably across the EU5 regions and the US. While the majority of nephrologists in the EU5 agree that all non-dialysis patients with suspected glomerular disease should undergo a kidney biopsy, nephrologists in some regions are far more reserved, while others are more likely to order a biopsy immediately upon suspecting glomerular disease.

Treatment goals vary across countries, with the majority of nephrologists in the UK and Germany aiming towards stabilizing eGFR and those in Italy aiming to keep proteinuria below 1 gram. In France and Spain, doctors increasingly target proteinuria below 500mg for IgAN patients. While most nephrologists agree that steroid minimization is key in treating IgAN patients, those in certain countries are more likely to treat earlier and more aggressively with steroids than others. The biggest opportunity highlighted throughout may be the potential utilization of SGLT2 inhibitors on this glomerular disease population.  

Looking towards the future, nephrologists most seek a new IgAN treatment that can slow chronic kidney disease (CKD) progression overall and significantly reduce proteinuria. Products evaluated in this research (and the US-based research) for familiarity and potential patient candidacy include: atacicept (Vera Therapeutics), atrasentan (Chinook), cemdisiran (Alnylam), IONIS-FB-L (IONIS), iptacopan (Novartis), narsoplimab (Omeros), Nefecon (Calliditas), sparsentan (Travere), and VIS649 (Otsuka and Visterra).

Nephrologists in the EU5, similarly to those in the US, have the greatest familiarity with Nefecon, sparsentan, and atrasentan – with familiarity peaking for certain products in different countries. When asked which IgAN pipeline product they would most like to see approved, again nephrologists’ opinions vary by geography, selecting different products as having the greatest potential.

Spherix will also be releasing the second annual US-based IgA nephropathy patient chart audit included in their RealWorld Dynamix™: IgA Nephropathy (US) service in Q1 2022, including insights from more than 400 IgAN patient charts. This data, in combination with data released in Q1 2021 of more than 450 IgAN patients, will provide pharmaceutical companies launching into this space unique perspectives on specific patient types, lab values (proteinuria and eGFR metrics, among others), treatment histories, and future courses of care).

Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years, highlighting market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

RealWorld Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns. 

Learn more about our services here.

About Spherix Global Insights

Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:
Kristen Henn, Business Development Manager
Email: [email protected]
www.spherixglobalinsights.com

SOURCE Spherix Global Insights



Source link

Related Posts

Heptanoic Acid Market Size to Grow by USD 604.03 million with 41% contribution from Europe, 17,000+ Technavio Reports

by MtR
August 10, 2022
0

Key Market Dynamics The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers,...

Caffeine Substitute Market to Observe Highest Growth of USD

by MtR
August 10, 2022
0

BIRMINGHAM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- A Qualitative Research Study accomplished by Data Bridge Market research's catalogue of 350...

Offshore Wind Power Market: 53% of Growth to Originate from Europe, Monopile Segment to be Significant for Revenue Generation

by MtR
August 10, 2022
0

Offshore Wind Power Market: Segmentation Analysis The market research report segments the offshore wind power market by Type (monopile, jacket, and others)...

High Visibility Clothing Market Size [2022-2028] To Reach

High Visibility Clothing Market Size [2022-2028] To Reach

by MtR
August 9, 2022
0

WASHINGTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global High Visibility Clothing Market finds...

IT spends in good shape; see continued strength in US, European markets: Infosys CEO Salil Parekh

by MtR
August 9, 2022
0

Infosys CEO Salil Parekh. (File photo)Bengaluru: India's second-largest IT services company Infosys is "comfortable" with the higher revenue growth guidance...

Load More
  • Trending
  • Comments
  • Latest

Bank of England tells ministers to intervene on digital currency ‘programming’

June 21, 2021

Tips for checking smoke alarms during daylight saving time

March 12, 2022

GLOBAL MARKETS-U.S. stocks follow Europe up; Treasury yields rise, dollar firm

July 9, 2021

What will Durham County education bonds pay for? A full list

July 8, 2022
African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

0
Maxum Foods releases Global Dairy Commodity Update for June

Maxum Foods releases Global Dairy Commodity Update for June

0
Letter: Perpetual bonds can help states fight hunger

Letter: Perpetual bonds can help states fight hunger

0
United Kingdom ETFs Are Riding the Re-Opening Momentum

United Kingdom ETFs Are Riding the Re-Opening Momentum

0

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Industrial Lubricants Market to Reach $71 Billion by 2027.

August 10, 2022

Recent News

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Categories

  • Asia
  • Bonds
  • Canada
  • Commodities
  • Cryptocurrencies
  • Currencies
  • Emerging Markets
  • ETFs
  • Europe & Middle East
  • IPOs
  • Latin America
  • Mutual Funds
  • Personal Finance
  • Real Estate
  • Retirement
  • Spending & Saving
  • Stocks
  • U.S. Markets
  • Privacy & Policy
  • About Us
  • Contact Us
  • Advertise with us

© 2021 Copyright Market-Reporter

No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate

© 2021 Copyright Market-Reporter